Novel Cationic Polymer Enhances Adenoviral Gene Therapy for Cancer

Strategic Insights -

Scientists in the United States have reported the development of a novel cationic polymer, EGDE-3,3', that significantly enhances adenoviral gene therapy for cancer. The polymer was found to increase infectivity and transgene expression, with a 100-fold reduction in the amount of adenovirus required to transduce 50-60% of cancer cells. This breakthrough has the potential to revolutionize cancer treatment, particularly for patients with bladder cancer. The study's findings suggest that novel biocompatible polymers may be useful in improving the delivery of adenoviral gene therapy.

Key Takeaways:

  • The novel cationic polymer EGDE-3,3' was found to enhance adenoviral gene therapy for cancer by increasing infectivity and transgene expression.
  • The amount of adenovirus required to transduce 50-60% of cancer cells was reduced 100-fold when Ad.GFP was preincubated with the EGDE-3,3' polymer.
  • Polyethyleneimine (pEI), a positively charged polymer currently used as a standard for enhancing adenoviral transduction, also increased infectivity, but transgene expression was consistently higher with EGDE-3,3'.
  • EGDE-3,3'-supplemented transduction of an adenovirus expressing an apoptosis inducing transgene, Ad.GFP-TRAIL, significantly enhanced the amount of cell death.
  • The study's findings suggest that novel biocompatible polymers may be useful in improving the delivery of adenoviral gene therapy.
  • The researchers concluded that their results indicate the potential of novel biocompatible polymers in improving adenoviral gene therapy.

Statistics:

  • 100-fold reduction in the amount of adenovirus required to transduce 50-60% of cancer cells with EGDE-3,3' polymer.
  • 50-60% transduction efficiency of bladder cancer cells with EGDE-3,3' polymer.
  • Higher transgene expression with EGDE-3,3' polymer compared to polyethyleneimine (pEI).
  • Significant enhancement of cell death with EGDE-3,3'-supplemented transduction of Ad.GFP-TRAIL.

Sources:

  • Molecular Pharmaceutics, "Polymer-Enhanced Adenoviral Transduction of CAR-Negative Bladder Cancer Cells" (2009)
  • Arizona State University, Department of Chemical Engineering
  • American Chemical Society, publisher of Molecular Pharmaceutics
  • Cancer Gene Therapy Week, via NewsRx.com.